Pulmonary Impact of PBK

A gene that is overexpressed in some aggressive cancers also appears to be key to the excessive cell proliferation that thickens the walls of pulmonary arteries and ultimately causes the right ventricle of the heart to fail, scientists report.

They have the first evidence that PBK, or PDZ-Binding Kinase, is upregulated in both animal models and the lung tissue of patients with progressive and deadly pulmonary hypertension, says Dr. David Fulton, director of the MCG Vascular Biology Center.

drawing of lungsThey’ve found that in pulmonary hypertension, PBK is “robustly” upregulated in the middle layer of the walls of pulmonary arteries, called the tunica media, where smooth muscle cells reside and where they along with elastic and connective tissue, help regulate the size of the passageway for blood, says Dr. Scott Barman, pulmonary vascular biologist in the MCG Department of Pharmacology and Toxicology.

The scientists also have found that adjustments they make, up and down, in PBK expression impact the proliferation of those smooth muscle cells.

Fulton and Barman are principal investigators on a $2.5 million grant from the National Heart, Lung and Blood Institute that is helping them further explore the pathway, including the impact of PBK inhibitors already under study for some of those aggressive cancers.

In their rat and mouse models of pulmonary hypertension, they have early evidence that PBK inhibitors reduce unhealthy remodeling of blood vessels and improve heart and lung function. In what is called a reversal model, which mimics how drugs would be used in people, when the animal models start to show signs of the disease, treatment is given and they get better, Barman says.

They are using two main PBK inhibitors — OTS514 and TOPK-32 — at different doses to see if, for example, higher doses mean further reduction in cell proliferation, Barman says. Small doses used in their work to date yielded “amelioration.”

PBK is known to be overexpressed in cancers, like bladder, lung, liver and brain tumors where its high expression is generally associated with a worse prognosis. In fact, the rapid cell division and resulting excessive cell production is similar in pulmonary hypertension and cancer, the scientists say.

The MCG scientists are the first to look at PBK in pulmonary hypertension. Fulton categorizes it as a — not the only — regulator of cell proliferation, and when it’s knocked out, animals still develop. But in pulmonary hypertension it’s an early player.

Looking upstream of PBK, they found that YAP1, yes associated protein 1, known to activate other genes that enable cell proliferation and quieten those that cause cell death, or apoptosis, (which can kill off excessive or otherwise unhealthy cells) also is upregulated in pulmonary hypertension, where it increases the activity of PBK in those smooth muscle cells inside the walls of pulmonary arteries.

Looking downstream they have found PBK in turn upregulates protein regulator of cytokinesis 1, or PRC1. Cytokinesis is when one cell divides into two cells and all together the bottom line is unhealthy remodeling of pulmonary arteries and pulmonary hypertension.

When they are done with the five-year term of the new NHLBI grant, they expect to have solid scientific evidence about whether PBK is the solid target they think, Barman says. The fact that inhibitors already exist should expedite the process of pursuing trials in humans from there, he says.

Like
Like Love Haha Wow Sad Angry

Readers’ Picks

For nearly 200 years, Augusta University and its legacy institutions have been centers of learning and drivers of discovery and innovation in Augusta, the state of Georgia and beyond. Our community of alumni, students, faculty and friends are amazing people living incredible lives and making invaluable contributions to our world.

We are pleased to publish four magazines in which we get to tell their stories: